# Cizzle Bio expands CIZ1B lung cancer testing into San Antonio

- Link: https://www.directorstalkinterviews.com/cizzle-bio-expands-ciz1b-lung-cancer-testing-into-san-antonio/4121269714
- Published: 2026-11-13T15:07:00+00:00
- Author: Amilia Stone

Cizzle Bio has confirmed that its CIZ1B lung cancer biomarker blood test is available
through licensed healthcare providers in the San Antonio metropolitan area, expanding
its US commercial coverage.

The test analyses a blood sample for a specific variant of the CIZ1 protein associated
with lung cancer. It is designed to provide additional information to healthcare
professionals when assessing patients for potential lung cancer.

The company is targeting patients with relevant risk factors, symptoms or previous
imaging findings. These may include smoking history, family history of lung cancer
and exposure to environmental or occupational risks.

The CIZ1B test is intended to complement existing screening and diagnostic procedures,
including low-dose computed tomography (LDCT). It does not replace imaging, biopsies
or specialist medical assessments.

Healthcare providers determine whether testing is appropriate and interpret the 
results alongside a patient’s medical history and other clinical information.

The San Antonio launch extends Cizzle Bio’s existing availability in the Dallas-
Fort Worth metropolitan area, giving the company access to another major US healthcare
market.

The expansion forms part of its efforts to increase access to CIZ1B testing and 
establish relationships with healthcare providers as it develops the commercial 
potential of its lung cancer biomarker technology.

_**Cizzle Biotechnology Holdings plc** (LON:CIZ) is a pioneering cancer diagnostics
company, originally a spin-out from the University of York, and now listed on the
London Stock Exchange._

Share on: